HKSE - Delayed Quote HKD

Antengene Corporation Limited (6996.HK)

0.780

-0.010

(-1.27%)

At close: January 28 at 11:58:52 AM GMT+8

Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025

Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from its Phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 (CLDN18.2 antibody-drug conjugate [ADC]) in patients with advanced or metastatic gastric cancer at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2025 (ASCO GI 2025).

PR Newswire 9 days ago

6996.HK
-1.27%
January 2025 Penny Stocks With Promising Potential

As global markets navigate a mixed economic landscape, with U.S. consumer confidence declining and major stock indices experiencing moderate gains, investors are keenly observing opportunities for growth. Penny stocks, often seen as smaller or newer companies with lower price points, continue to attract attention due to their potential for significant returns when backed by strong financials. This article highlights three promising penny stocks that combine solid balance sheets with the...

Simply Wall St. 28 days ago

6996.HK
-1.27%
AIT-F.BK

AIT-R.BK
Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that it presented the latest data from two clinical studies of selinexor in two posters at the 2024 American Society of Hematology Annual Meeting (ASH 2024).

PR Newswire last month

6996.HK
-1.27%
Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the new indication of XPOVIO® (selinexor) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who have received at least two lines of systematic therapy, has bee

PR Newswire 2 months ago

6996.HK
-1.27%
Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present results from three programs at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC 2024) to be held in Houston, the United States from November 6-10, 2024.

PR Newswire 2 months ago

6996.HK
-1.27%
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present the latest data from two clinical studies of selinexor in two Posters at the 2024 American Society of Hematology Annual Meeting (ASH 2024), taking place on December 7-10, 2024, in San Diego, CA, the United States.

PR Newswire 2 months ago

6996.HK
-1.27%
Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the South Korean Ministry of Food and Drug Safety (MFDS) has approved a supplemental New Drug Application (sNDA) for XPOVIO® (selinexor) in combination with bortezomib and dexamethasone for the tre

PR Newswire 3 months ago

6996.HK
-1.27%
Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present three programs at the 2024 Society of Immunology in Cancer Annual Meeting (SITC 2024) to be held in Houston from November 6-10, 2024.

PR Newswire 3 months ago

6996.HK
-1.27%
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the Thailand Food and Drug Administration has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for two indications: (1) In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple

PR Newswire 4 months ago

6996.HK
-1.27%
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024

Antennova, a clinical-stage biotech company focused on oncology today announced that it presented the latest data of CD73 small molecule inhibitor ATN-037 in a Mini Oral presentation at the 2024 European Society of Medical Oncology Congress (ESMO Congress 2024).

PR Newswire 4 months ago

6996.HK
-1.27%
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization

Antengene Corporation (6996.HK) today announced its interim results for the period ending June 30, 2024, along with several significant milestones achieved in recent months.

PR Newswire 5 months ago

6996.HK
-1.27%
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for two indications: (1) In combination with bortezomib and dexamethasone for the treatment of adult patients

PR Newswire 5 months ago

6996.HK
-1.27%
Antennova Announces CD73 Small Molecule Inhibitor Accepted for Mini Oral Presentation at ESMO Congress 2024

Antennova, a clinical-stage biotech company focused on oncology today announced that the orally administered CD73 small molecule inhibitor ATN-037 (also known as ATG-037) has been accepted for Mini Oral presentation at the 2024 European Society of Medical Oncology Congress (EMSO Congress 2024), taking place from September 13th to September 17th at the Fira Barcelona Gran Via in Barcelona, Spain.

PR Newswire 5 months ago

6996.HK
-1.27%
XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the China National Medical Products Administration (NMPA) has approved a new indication of XPOVIO® (selinexor) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL

PR Newswire 6 months ago

6996.HK
-1.27%
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that South Korea's National Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO® (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM). The drug is expected to be offic

PR Newswire 7 months ago

6996.HK
-1.27%
Antengene To Present One Oral and Four Abstracts at ASCO 2024

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced one oral presentation, three poster presentations and a journal publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31st to June 4th at the McCormick Place Convention Center in Chica

PR Newswire 8 months ago

6996.HK
-1.27%
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four abstracts (including one oral presentation and three poster presentations) at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place from May 31st to June 4th at the McCormick Place C

PR Newswire 9 months ago

6996.HK
-1.27%
Antengene Presents Four Preclinical Posters at AACR 2024

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the Unit

PR Newswire 9 months ago

6996.HK
-1.27%
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced its full year results for the period ended December 31, 2023, and provided an update on the impressive progress of its clinical development pipeline over the last several months.

PR Newswire 10 months ago

6996.HK
-1.27%
Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has initiated the dose expansion portion of the Phase II CLINCH study of ATG-022 (Claudin 18.2 antibody-drug conjugate[ADC]) in China and Australia. Prior to this, the CLINCH trial has already produced promising

PR Newswire 10 months ago

6996.HK
-1.27%

Performance Overview

Return	6996.HK	HANG SENG INDEX
YTD	+16.42%	+0.92%
1-Year	-47.30%	+26.79%
3-Year	-86.36%	-15.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Antengene Corporation Limited (6996.HK)

Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025

January 2025 Penny Stocks With Promising Potential

Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024

Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Antennova Announces CD73 Small Molecule Inhibitor Accepted for Mini Oral Presentation at ESMO Congress 2024

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Antengene To Present One Oral and Four Abstracts at ASCO 2024

Antengene Announces One Oral and Three Poster Presentations at ASCO 2024

Antengene Presents Four Preclinical Posters at AACR 2024

Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline

Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

Performance Overview